Tharimmune Receives Nasdaq Non-Compliance Notice for Board Independence
Summary
Tharimmune, Inc. received a Nasdaq non-compliance notice for failing to meet board independence requirements but expects to regain compliance after an upcoming shareholder meeting.
Key Events
-
Nasdaq Non-Compliance Notification
Tharimmune, Inc. received a notification from The Nasdaq Stock Market LLC on January 9, 2026, for noncompliance with Listing Rule 5605.
-
Board Independence Requirement
The noncompliance is due to the requirement that a majority of the Board of Directors be comprised of independent directors, which the company currently does not meet.
-
Reason for Non-Compliance
The issue stems from the resignations of two directors (Nancy Davis and Sanam Parikh) effective November 6, 2025, and the subsequent election of Mark Wendland, leaving one board vacancy and an insufficient number of independent directors.
-
Cure Period Granted
Nasdaq has granted a cure period until the earlier of the company's next annual shareholders' meeting or November 6, 2026, to regain compliance.
Analysis
Tharimmune, Inc. received a formal notification from Nasdaq regarding its noncompliance with the listing rule requiring a majority of its Board of Directors to be independent. This issue arose from recent director resignations and appointments, creating a temporary vacancy and an imbalance in board independence. While the company has a cure period until November 6, 2026, and expects to resolve the matter by electing two new independent directors at a special shareholder meeting on January 30, 2026, such notices highlight governance risks and can impact investor confidence. Successful resolution is crucial to maintain its Nasdaq listing.
At the time of this filing, THAR was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $110.7M. The 52-week trading range was $0.95 to $9.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.